Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell Lung Cancer in a randomised phase II study

Abstract

The EORTC Lung Cancer Cooperative group performed a randomised phase II study in patients with small cell lung cancer comparing the standard cyclophosphamide/doxorubicin/etoposide (CDE) regimen with two regimens containing the new and active cisplatin derivative, carboplatin, 400 mg/m 2 in combination with ifosfamide, a drug without important myelotoxicity, at a dose of 5 g/m 2 (IMP) or the non-myelotoxic drug vincristine twice 2 mg (VP). Of 178 evaluable patients, 63 received CDE [30 limited disease (LD), 33 extensive disease (ED)], 55 received IMP (22 LD, 33 ED) and 60 (26 LD, 34 ED) were treated with VP. The response duration was not statistically different: CDE 31 weeks, IMP 29 weeks and VP 21 weeks. The time to progression after CDE was 28 weeks, IMP 24 weeks and VP 17 weeks. This was significantly shorter after VP than after CDE ( P = 0.017). The 60% response rate of the VP combination was low compared with CDE (83%) and IMP (77%). Toxicity of all three regimens was acceptable, and dose reduction for myelosuppression was necessary in only a minority of the patients. We conclude from this study that the combination of carboplatin, at the maximally tolerated dose of 400 mg/m 2, in combination with ifosfamide 5 g/m 2, is an active regimen with efficacy comparable with the standard CDE regimen.